Clinical trials: sponsored by Zhejiang Cancer Hospital
Thrombocytopenia, Cancer Treatment-induced Thrombocytopenia
Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT)
This study is a prospective, single-center, open-label, single-arm clinical trial to assess the safety and efficacy of umbilical cord blood in cancer treatment-induced thrombocytopenia (CTIT) patients.
- Trial name
- NCT07441720
- Testing
- umbilical cord blood
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Zhejiang Cancer Hospital
Non-small Cell Lung Cancer (NSCLC) Stage IV, Locally Advanced Non-Small Cell Lung Cancer
An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung Cancer
This exploratory clinical study evaluates the efficacy and safety of combining benmelstobart (a PD-L1 inhibitor) with anlotinib (a multi-target anti-angiogenic TKI) as a first-line, chemotherapy-free treatment for elderly…
- Conditions
- Non-small Cell Lung Cancer (NSCLC) Stage IV, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
- Trial name
- BEACON-OLD (NCT07849712)
- Testing
- Benmelstobart Combined With Anlotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
Research on AI Models for Predicting Breast Cancer Treatment Effectiveness to Guide Her-2 Targeted ADC Therapy
This study aims to develop an AI-based predictive tool to help clinicians more accurately determine whether breast cancer patients can benefit from HER-2-targeted antibody-drug conjugate (T-DXd) therapy before treatment.
- Trial name
- NCT07689929
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Zhejiang Cancer Hospital
Ovarian Cancer, HER2
Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment
Ovarian cancer exhibits the highest mortality rate among gynecological malignancies. Currently, the combination of paclitaxel and carboplatin remains the standard first-line chemotherapy regimen for neoadjuvant or postoperative…
- Trial name
- NCT07285941
- Testing
- RC48 + Carboplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer Females
A Real-world Study on the Compliance of OFS-assisted Endocrine Therapy for Hormone Receptor-positive(HR+) Premenopausal Breast Cancer
The goal of this observational study is to observe the long-term prognosis of patients with early HR-positive premenopausal breast cancer.
- Trial name
- NCT07180914
- Volunteers
- 300 people
- Sponsor
- Zhejiang Cancer Hospital
Female Breast Cancer Patients, Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer
Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer
This is an open-label, single-arm, exploratory study planned to include 40 patients with HRD-positive HR +/HER2- advanced breast cancer treated with Adebrelimab in combination with fluzoparib.
- Conditions
- Female Breast Cancer Patients, Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer, HRD Positive Advanced Breast Cancer
- Trial name
- NCT06254066
- Testing
- Adebrelimab plus Fluzoparib
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Cancer, Signet Ring Cell Carcinoma
Mechanism of Gastric Signet Ring Cell Carcinoma Based on Microproteomics
Gastric signet ring cell carcinoma (GSRCC) possesses unique epidemiology and pathogenesis in the field of cancer, but its incidence is low.
- Trial name
- NCT05985577
- Testing
- Without any intervention
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Zhejiang Cancer Hospital
Second Line Treatment of Gastric Cancer
Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
This study is a multicenter, open, and randomized clinical phase II exploratory study. The "pick the winner" study design is used to determine and select which chemotherapy drug (irinotecan vs.
- Trial name
- NCT05669807
- Testing
- Camrelizumab, Albumin-Bound Paclitaxel, Irinotecan
- Volunteers
- 184 people
- Sponsor
- Zhejiang Cancer Hospital
Febrile Neutropenia
Prophylactic Use of PEG-rhG-CSF in Medium-high Risk of FN in Chemotherapy of Breast Cancer
This clinical study is a multiple center, registering and real-world conditional research. The breast cancer patients planning for chemotherapy evaluated with medium-high risk of febrile neutropenia (FN) are recruited, receiving…
- Trial name
- NCT03618810
- Testing
- PEGCSF first level prophylactic use, PEGCSF second level prophylactic use
- Volunteers
- 2,000 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma, PET/MR
PET/MR in Locally Advanced Nasopharyngeal Carcinoma
PET/MR in Locally Advanced Nasopharyngeal Carcinoma
- Trial name
- NCT03657017
- Testing
- PET/MR
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Zhejiang Cancer Hospital
Non-small Cell Lung Cancer, Aquired Resistance
Acquired Resistant Mechanism of the First-generation EGFR TKIs
Patients with advanced non-small-cell lung cancer (NSCLC) harboring sensitive epithelial growth factor receptor (EGFR) mutations invariably develop acquired resistance to EGFR tyrosine kinase inhibitors (TKIs).
- Conditions
- Non-small Cell Lung Cancer, Aquired Resistance, EGFR TKIs
- Trial name
- NCT02804217
- Testing
- Genetic: mutation profile
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital